



NATIONAL MEDICAL SERVICES

April 20, 2005

Dear Valued Client:

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled the enclosed packet of important changes regarding a number of tests we perform. Listed below are the types of changes included in this packet.

Category	Type of Change
I.	Tests that have had changes to their method/CPT code, units of measurement, scope of analysis or specimen requirements
II.	Tests that have been discontinued
III.	Tests that have had reference comment changes

Please be advised that the changes listed in this packet will go into effect on **August 1, 2005**. Please use this packet of information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

We apologize if this causes you any inconvenience. If you have any questions about the information contained in this packet, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of National Medical Services and your assistance in implementing these changes.

Sincerely,

National Medical Services, Inc.

Database Changes - Summary

Categories:

- I: Method/CPT Code, Units, Scope of Analysis and Specimen Requirements
- II: Deleted tests
- III: Reference comment changes

Test Code	Test Name	Category		
		I	II	III
0093U	Acetonitrile Biouptake Survey, Urine			•
0152U	Acrylonitrile Overexposure Survey, Urine			•
0264U	Aluminum, Urine			•
0273U	Aminophenol, para-, Urine			•
0405B	Anticonvulsants Panel, Blood			•
0405SP	Anticonvulsants Panel, Serum/Plasma			•
5450B	Antidepressants Confirmation, Blood	•		•
5450FL	Antidepressants Confirmation, Fluid	•		
5450SP	Antidepressants Confirmation, Serum/Plasma	•		•
5450TI	Antidepressants Confirmation, Tissue	•		
5450U	Antidepressants Confirmation, Urine	•		•
4655B	Antidepressants Panel 1, Blood	•		•
4655FL	Antidepressants Panel 1, Fluid	•		
4655SP	Antidepressants Panel 1, Serum/Plasma	•		•
4655TI	Antidepressants Panel 1, Tissue	•		
4655U	Antidepressants Panel 1, Urine	•		•
4661B	Antidepressants Panel 2, Blood		•	
4661FL	Antidepressants Panel 2, Fluid		•	
4661SP	Antidepressants Panel 2, Serum/Plasma		•	
4661TI	Antidepressants Panel 2, Tissue		•	
4661U	Antidepressants Panel 2, Urine		•	
8700B	Antidepressants Panel, Blood	•		•
8700FL	Antidepressants Panel, Fluid	•		
8700SP	Antidepressants Panel, Serum/Plasma	•		•
8700TI	Antidepressants Panel, Tissue	•		
8700U	Antidepressants Panel, Urine	•		•
9431B	Antidepressants Screen, Blood	•		•
9431SP	Antidepressants Screen, Serum/Plasma	•		•
9431TI	Antidepressants Screen, Tissue	•		
9431U	Antidepressants Screen, Urine	•		•
0408B	Antihistamines Panel, Blood			•
0408SP	Antihistamines Panel, Serum/Plasma			•
0408U	Antihistamines Panel, Urine			•
0454U	Aromatic Amines Panel, Urine		•	
0785B	Aromatic Solvents Exposure Panel, Blood			•
0785SP	Aromatic Solvents Exposure Panel, Serum/Plasma			•
0456U	Aromatic Solvents Exposure Panel, Urine		•	
0457U	Aromatic Solvents Profile, Urine	•		•
5225B	Barbiturates Confirmation, Blood			•
5651B	Barbiturates Confirmation, Blood			•
5225SP	Barbiturates Confirmation, Serum/Plasma			•
5651SP	Barbiturates Confirmation, Serum/Plasma			•
8620B	Barbiturates Panel, Blood			•
8620SP	Barbiturates Panel, Serum/Plasma			•
0680B	Bismuth, Blood			•
5639B	Brucine Confirmation, Blood		•	

National Medical Services, Inc.

3701 Welsh Road, Willow Grove, PA 19090

800-522-6671

Database Changes - Summary

Test Code	Test Name	Category		
		I	II	III
5639FL	Brucine Confirmation, Fluid		•	
5639SP	Brucine Confirmation, Serum/Plasma		•	
5639TI	Brucine Confirmation, Tissue		•	
5639U	Brucine Confirmation, Urine		•	
9119B	Brucine Screen, Blood		•	
9119FL	Brucine Screen, Fluid		•	
9119SP	Brucine Screen, Serum/Plasma		•	
9119TI	Brucine Screen, Tissue		•	
9119U	Brucine Screen, Urine		•	
0780B	Brucine, Blood		•	
0780FL	Brucine, Fluid		•	
0780SP	Brucine, Serum/Plasma		•	
0780TI	Brucine, Tissue		•	
0780U	Brucine, Urine		•	
5464B	Buclizine Confirmation, Blood		•	
5464FL	Buclizine Confirmation, Fluid		•	
5464SP	Buclizine Confirmation, Serum/Plasma		•	
5464TI	Buclizine Confirmation, Tissue		•	
5464U	Buclizine Confirmation, Urine		•	
9120B	Buclizine Screen, Blood		•	
9120FL	Buclizine Screen, Fluid		•	
9120SP	Buclizine Screen, Serum/Plasma		•	
9120TI	Buclizine Screen, Tissue		•	
9120U	Buclizine Screen, Urine		•	
0790B	Buclizine, Blood		•	
0790FL	Buclizine, Fluid		•	
0790SP	Buclizine, Serum/Plasma		•	
0790TI	Buclizine, Tissue		•	
0790U	Buclizine, Urine		•	
1001B	Carbon Monoxide Hemoglobin, Blood		•	
1001R	Carbon Monoxide Hemoglobin, RBCs		•	
1042SP	Cesium, Serum/Plasma			•
2216B	Chlorinated Hydrocarbons, Blood			•
2215B	Chlorinated Solvents, Blood			•
2215SP	Chlorinated Solvents, Serum/Plasma			•
5481B	Chlormezanone Confirmation, Blood		•	
5481FL	Chlormezanone Confirmation, Fluid		•	
5481SP	Chlormezanone Confirmation, Serum/Plasma		•	
5481TI	Chlormezanone Confirmation, Tissue		•	
5481U	Chlormezanone Confirmation, Urine		•	
9314B	Chlormezanone Screen, Blood		•	
9314FL	Chlormezanone Screen, Fluid		•	
9314SP	Chlormezanone Screen, Serum/Plasma		•	
9314TI	Chlormezanone Screen, Tissue		•	
9314U	Chlormezanone Screen, Urine		•	
1090B	Chlormezanone, Blood		•	
1090FL	Chlormezanone, Fluid		•	
1090SP	Chlormezanone, Serum/Plasma		•	
1090TI	Chlormezanone, Tissue		•	
1090U	Chlormezanone, Urine		•	

National Medical Services, Inc.

3701 Welsh Road, Willow Grove, PA 19090

800-522-6671

Database Changes - Summary

Test Code	Test Name	Category		
		I	II	III
1330SP	Copper, Serum/Plasma			•
1350U	Cresols, Urine			•
1361U	Cumene Exposure Uptake Survey, Urine	•		
1410U	Cyclohexanol, Urine	•		•
5699B	Dezocine Confirmation, Blood		•	
5699SP	Dezocine Confirmation, Serum/Plasma		•	
5699U	Dezocine Confirmation, Urine		•	
9125B	Dezocine Screen, Blood		•	
9125SP	Dezocine Screen, Serum/Plasma		•	
9125U	Dezocine Screen, Urine		•	
1550B	Dichloroethane, Blood	•		•
1550SP	Dichloroethane, Serum/Plasma	•		•
1550U	Dichloroethane, Urine	•		•
1693B	Dimethyltryptamine, Blood			•
1693SP	Dimethyltryptamine, Serum/Plasma			•
1760B	Diphenhydramine, Blood			•
1760SP	Diphenhydramine, Serum/Plasma			•
1760U	Diphenhydramine, Urine			•
1808B	Donnatal, Blood			•
1808SP	Donnatal, Serum/Plasma			•
1931B	EP (FEP), Blood		•	
1930B	EP (FEP), Pediatric, Blood	•		•
1930R	EP (FEP), Pediatric, RBCs		•	
1931R	EP (FEP), RBCs		•	
1959R	Ethambutol, RBCs			•
2068B	Famotidine, Blood	•		
2068SP	Famotidine, Serum/Plasma	•		
2154SP	Ganciclovir, Serum/Plasma			•
2160B	Glutethimide, Blood			•
2160SP	Glutethimide, Serum/Plasma			•
5527B	Haloperidol Confirmation, Blood			•
5527SP	Haloperidol Confirmation, Serum/Plasma			•
9182B	Haloperidol Screen, Blood			•
9182SP	Haloperidol Screen, Serum/Plasma			•
2220B	Haloperidol, Blood			•
2220SP	Haloperidol, Serum/Plasma			•
2232B	Heavy Metals Panel, Blood			•
2241U	Heavy Metals Panel, Urine			•
2242U	Heavy Metals Panel, Urine			•
2291U	Hexanol, 1 and 2-, Urine	•		•
2306U	Hippuric Acid and Methylhippuric Acid, Urine			•
2300U	Hippuric Acid, Urine			•
2321B	Hydrocarbon and Oxygenated Volatiles Panel, Blood			•
2321SP	Hydrocarbon and Oxygenated Volatiles Panel, Serum/Plasma			•
2340B	Hydrocodone, Blood			•
2340SP	Hydrocodone, Serum/Plasma			•
2417B	Inhalant Intoxicants Survey, Blood			•
2408B	Inhalants Panel, Blood			•
2415B	Inhalants Panel, Blood			•
2415SP	Inhalants Panel, Serum/Plasma			•

National Medical Services, Inc.

3701 Welsh Road, Willow Grove, PA 19090

800-522-6671

Database Changes - Summary

Test Code	Test Name	Category		
		I	II	III
2413B	Inhalants Panel, Solvents and Gases, Blood			•
2411B	Inhalants Panel, Solvents, Blood			•
2411SP	Inhalants Panel, Solvents, Serum/Plasma			•
2512B	Lidocaine and Metabolite (MEGX), Blood			•
2512SP	Lidocaine and Metabolite (MEGX), Serum/Plasma			•
2512U	Lidocaine and Metabolite (MEGX), Urine			•
2510B	Lidocaine, Blood			•
2510SP	Lidocaine, Serum/Plasma			•
2510U	Lidocaine, Urine			•
2557U	Mandelic Acid, Urine			•
5551B	Mazindol Confirmation, Blood		•	
5551FL	Mazindol Confirmation, Fluid		•	
5551SP	Mazindol Confirmation, Serum/Plasma		•	
5551TI	Mazindol Confirmation, Tissue		•	
5551U	Mazindol Confirmation, Urine		•	
9194B	Mazindol Screen, Blood		•	
9194FL	Mazindol Screen, Fluid		•	
9194SP	Mazindol Screen, Serum/Plasma		•	
9194TI	Mazindol Screen, Tissue		•	
9194U	Mazindol Screen, Urine		•	
2575B	Mazindol, Blood		•	
2575FL	Mazindol, Fluid		•	
2575SP	Mazindol, Serum/Plasma		•	
2575TI	Mazindol, Tissue		•	
2575U	Mazindol, Urine		•	
5552B	Mebutamate Confirmation, Blood		•	
5552FL	Mebutamate Confirmation, Fluid		•	
5552SP	Mebutamate Confirmation, Serum/Plasma		•	
5552TI	Mebutamate Confirmation, Tissue		•	
5552U	Mebutamate Confirmation, Urine		•	
9195B	Mebutamate Screen, Blood		•	
9195FL	Mebutamate Screen, Fluid		•	
9195SP	Mebutamate Screen, Serum/Plasma		•	
9195TI	Mebutamate Screen, Tissue		•	
9195U	Mebutamate Screen, Urine		•	
2580B	Mebutamate, Blood		•	
2580FL	Mebutamate, Fluid		•	
2580SP	Mebutamate, Serum/Plasma		•	
2580TI	Mebutamate, Tissue		•	
2580U	Mebutamate, Urine		•	
2620B	Mephentoin and Metabolite, Blood			•
2620SP	Mephentoin and Metabolite, Serum/Plasma			•
2630B	Mephobarbital and Metabolite, Blood			•
2630SP	Mephobarbital and Metabolite, Serum/Plasma			•
2675B	Mercury Exposure Survey, Blood			•
2670B	Mercury, Blood			•
2697B	Metals Acute Poisoning Panel, Blood			•
2693B	Metals/Metalloids Acute Poisoning Panel, Blood			•
2661B	Metals/Metalloids Panel 1, Blood			•
2663B	Metals/Metalloids Panel 3, Blood			•

National Medical Services, Inc.

3701 Welsh Road, Willow Grove, PA 19090

800-522-6671

Database Changes - Summary

Test Code	Test Name	Category		
		I	II	III
6311B	Metals/Metalloids Panel, Blood			•
9292U	Methylenedioxyamphetamine Screen, Urine			•
2584U	Methylenedioxyamphetamine, Urine			•
9293U	Methylenedioxymethamphetamine and Metabolite Screen, Urine			•
3020B	Methylphenidate and Metabolite, Blood			•
3020SP	Methylphenidate and Metabolite, Serum/Plasma			•
8673B	Morphine - Free and Total, Blood			•
8673SP	Morphine - Free and Total, Serum/Plasma			•
8672B	Morphine - Total (Conjugated and Unconjugated), Blood			•
8672SP	Morphine - Total (Conjugated and Unconjugated), Serum/Plasma			•
8367B	Natural Gas and Inhalants Survey, Blood			•
3148B	Nicotine and Metabolite, Blood			•
3148SP	Nicotine and Metabolite, Serum/Plasma			•
5593U	Nortriptyline Confirmation, Urine	•		
9433U	Nortriptyline Screen, Urine	•		
1352U	o-Cresol, Urine			•
5645B	Opiates - Free (Unconjugated) Confirmation, Blood			•
5723B	Opiates - Free (Unconjugated) Confirmation, Blood			•
5645SP	Opiates - Free (Unconjugated) Confirmation, Serum/Plasma			•
5723SP	Opiates - Free (Unconjugated) Confirmation, Serum/Plasma			•
8660B	Opiates - Free (Unconjugated), Blood			•
8660SP	Opiates - Free (Unconjugated), Serum/Plasma			•
8671B	Opiates - Free and Total, Blood			•
8671SP	Opiates - Free and Total, Serum/Plasma			•
3256B	Opiates - Total (Conjugated/Unconjugated), Blood			•
8670B	Opiates - Total (Conjugated/Unconjugated), Blood			•
8670R	Opiates - Total (Conjugated/Unconjugated), RBCs			•
8670SP	Opiates - Total (Conjugated/Unconjugated), Serum/Plasma			•
2302U	Organic Acids Panel, Urine			•
3250SP	Oxalate, Serum/Plasma			•
8667B	Oxycodone and Metabolite, Blood			•
8667SP	Oxycodone and Metabolite, Serum/Plasma			•
5557B	Oxycodone Confirmation, Blood			•
5557SP	Oxycodone Confirmation, Serum/Plasma			•
3270B	Oxycodone, Blood			•
3270SP	Oxycodone, Serum/Plasma			•
3292B	Palladium, Blood			•
3292R	Palladium, RBCs			•
3292SP	Palladium, Serum/Plasma			•
3292U	Palladium, Urine			•
3430B	Perchloroethylene, Blood			•
3430SP	Perchloroethylene, Serum/Plasma			•
3435B	Percocet, Blood			•
3435SP	Percocet, Serum/Plasma			•
3436B	Percodan, Blood			•
3436SP	Percodan, Serum/Plasma			•
3447P	Pesticides/Insecticides Screen, Plasma		•	
3445P	Pesticides/Insecticides Survey, Plasma		•	
3451P	Pesticides/Insecticides Survey, Plasma		•	
3453P	Pesticides/Insecticides Survey, Plasma		•	

National Medical Services, Inc.

3701 Welsh Road, Willow Grove, PA 19090

800-522-6671

Database Changes - Summary

Test Code	Test Name	Category		
		I	II	III
5544B	Phenobarbital Confirmation, Blood			•
5544SP	Phenobarbital Confirmation, Serum/Plasma			•
9416B	Phenobarbital Screen, Blood			•
9416SP	Phenobarbital Screen, Serum/Plasma			•
3580B	Phenobarbital, Blood			•
8633B	Phenobarbital, Blood			•
3580SP	Phenobarbital, Serum/Plasma			•
3584SP	Phenobarbital, Serum/Plasma			•
8633SP	Phenobarbital, Serum/Plasma			•
3621U	Phenol Exposure, Urine			•
3619B	Phenols, Blood		•	
3619SP	Phenols, Serum/Plasma		•	
3619U	Phenols, Urine		•	
3660FL	Phenothiazines (Total Undifferentiated) Screen, Fluid		•	
3660U	Phenothiazines (Total Undifferentiated) Screen, Urine		•	
5653FL	Phenothiazines (Total) Confirmation, Fluid		•	
5653U	Phenothiazines (Total) Confirmation, Urine		•	
5545SP	Phenothiazines Confirmation, Serum/Plasma			•
8680B	Phenothiazines Panel, Blood			•
8680SP	Phenothiazines Panel, Serum/Plasma			•
9420SP	Phenothiazines Screen, Serum/Plasma			•
3658FL	Phenothiazines Total Undifferentiated, Fluid		•	
3658U	Phenothiazines Total Undifferentiated, Urine		•	
3900B	Primidone, Phenobarbital and PEMA, Blood			•
3900SP	Primidone, Phenobarbital and PEMA, Serum/Plasma			•
4022B	Pseudoephedrine vs Ephedrine Differentiation, Blood		•	
4022FL	Pseudoephedrine vs Ephedrine Differentiation, Fluid		•	
4022ME	Pseudoephedrine vs Ephedrine Differentiation, Meconium		•	
4022SP	Pseudoephedrine vs Ephedrine Differentiation, Serum/Plasma		•	
4022TI	Pseudoephedrine vs Ephedrine Differentiation, Tissue		•	
4022U	Pseudoephedrine vs Ephedrine Differentiation, Urine		•	
4070SP	Quinidine, Serum/Plasma			•
4071SP	Quinidine, Serum/Plasma			•
4072SP	Quinidine, Serum/Plasma			•
5434SP	Quinine/Quinidine Confirmation, Serum/Plasma			•
5435SP	Quinine/Quinidine Confirmation, Serum/Plasma (Forensic)			•
4075SP	Quinine/Quinidine Differentiation, Serum/Plasma			•
4124SP	Rubidium, Serum/Plasma			•
6317U	Semi-Conductor Panel, Urine			•
4200R	Silver, RBCs			•
0871B	Solvent Exposure Profile, Blood			•
0872U	Solvent Profile, Urine	•		•
4209B	Stimulant Excitants Panel 1, Blood		•	
4209SP	Stimulant Excitants Panel 1, Serum/Plasma		•	
4213U	Styrene Exposure Profile, Urine			•
4230U	Styrene Exposure Survey, Urine			•
4232B	Styrene, Blood	•		•
4232SP	Styrene, Serum/Plasma	•		•
4320U	Tellurium, Urine			•
4450B	Thiopental and Metabolite, Blood			•

National Medical Services, Inc.

3701 Welsh Road, Willow Grove, PA 19090

800-522-6671

Database Changes - Summary

Test Code	Test Name	Category		
		I	II	III
4450SP	Thiopental and Metabolite, Serum/Plasma			•
5693B	Thioridazine and Metabolite Confirmation, Blood			•
5693SP	Thioridazine and Metabolite Confirmation, Serum/Plasma			•
9427B	Thioridazine and Metabolite Screen, Blood			•
9427SP	Thioridazine and Metabolite Screen, Serum/Plasma			•
4461B	Thioridazine and Metabolite, Blood			•
8689B	Thioridazine and Metabolite, Blood			•
4461SP	Thioridazine and Metabolite, Serum/Plasma			•
8689SP	Thioridazine and Metabolite, Serum/Plasma			•
4511B	Toluene Biouptake Survey, Blood			•
4511U	Toluene Biouptake Survey, Urine			•
4512U	Toluene Exposure Panel, Urine			•
4513U	Toluene Exposure Panel, Urine			•
4510B	Toluene, Blood			•
4510SP	Toluene, Serum/Plasma			•
5626B	Tramadol and Metabolite Confirmation, Blood			•
5626SP	Tramadol and Metabolite Confirmation, Serum/Plasma			•
9288B	Tramadol and Metabolite Screen, Blood			•
9288SP	Tramadol and Metabolite Screen, Serum/Plasma			•
4531B	Tramadol and Metabolite, Blood			•
4531SP	Tramadol and Metabolite, Serum/Plasma			•
4772B	Vicodin, Blood			•
4772SP	Vicodin, Serum/Plasma			•
4870B	Zirconium, Blood			•
4870R	Zirconium, RBCs			•
4870SP	Zirconium, Serum/Plasma			•
5796U	Zolpidem Confirmation, Urine			•
9498U	Zolpidem Screen, Urine			•
2483B	Zolpidem, Blood			•
2483SP	Zolpidem, Serum/Plasma			•

National Medical Services, Inc.

3701 Welsh Road, Willow Grove, PA 19090

800-522-6671

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code Changes	Unit Changes
4655B	Antidepressants Panel 1, Blood		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypramine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Order of reported analytes was changed.			
4655FL	Antidepressants Panel 1, Fluid		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypramine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Order of reported analytes was changed.			
4655SP	Antidepressants Panel 1, Serum/Plasma		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypramine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Order of reported analytes was changed.			
4655TI	Antidepressants Panel 1, Tissue		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypramine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Order of reported analytes was changed.			
4655U	Antidepressants Panel 1, Urine		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypramine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Order of reported analytes was changed.			
5450B	Antidepressants Confirmation, Blood		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypramine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Mirtazapine [ng/mL; GC/MS] was added. Order of reported analytes was changed.			

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code Changes	Unit Changes
5450FL	Antidepressants Confirmation, Fluid		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Mirtazapine [ng/mL; GC/MS] was added. Order of reported analytes was changed.			
5450SP	Antidepressants Confirmation, Serum/Plasma		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Mirtazapine [ng/mL; GC/MS] was added. Order of reported analytes was changed.			
5450TI	Antidepressants Confirmation, Tissue		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Mirtazapine [ng/g; GC/MS] was added. Order of reported analytes was changed.			
5450U	Antidepressants Confirmation, Urine		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Mirtazapine [ng/mL; GC/MS] was added. Order of reported analytes was changed.			
8700B	Antidepressants Panel, Blood		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Order of reported analytes was changed.			
8700FL	Antidepressants Panel, Fluid		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Order of reported analytes was changed.			

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code Changes	Unit Changes
8700SP	Antidepressants Panel, Serum/Plasma		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypramine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Order of reported analytes was changed.			
8700TI	Antidepressants Panel, Tissue		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypramine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Order of reported analytes was changed.			
8700U	Antidepressants Panel, Urine		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypramine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Order of reported analytes was changed.			
9431B	Antidepressants Screen, Blood		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypramine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Mirtazapine [ng/mL; GC] was added. Order of reported analytes was changed.			
9431SP	Antidepressants Screen, Serum/Plasma		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypramine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Mirtazapine [ng/mL; GC] was added. Order of reported analytes was changed.			
9431TI	Antidepressants Screen, Tissue		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypramine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Mirtazapine [ng/mL; GC] was added. Order of reported analytes was changed.			

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code Changes	Unit Changes
9431U	Antidepressants Screen, Urine		
Scope of Analysis: Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine Duplicate Nortriptyline and Desipramine compounds were removed. Mirtazapine [ng/mL; GC] was added. Order of reported analytes was changed.			
0457U	Aromatic Solvents Profile, Urine		
Scope of Analysis: Creatinine, o-Cresol, o-Cresol (Creatinine correction), p-and/or m-Cresol, Phenol, Phenol (Creatinine correction), Ethylphenol, Ethylphenol (Creatinine correction), Hippuric Acid, Hippuric Acid (Creatinine correction), Mandelic Acid, Mandelic Acid (Creatinine correction), Phenylglyoxylic Acid, Phenylglyoxylic Acid (Creatinine correction), Methylhippuric Acid, Methylhippuric Acid (Creatinine correction), S-Phenylmercapturic Acid, S-Phenylmercapturic Acid (Creatinine correction), t,t-Muconic Acid, t,t-Muconic Acid (Creatinine correction) p-and/or m-Cresol [mg/L; GC], S-Phenylmercapturic Acid [mcg/L; LC/MS/MS; new CPT=82542], S-Phenylmercapturic Acid (Creatinine correction) [mcg/g; LC/MS/MS], t,t-Muconic Acid [mcg/L; LC/MS/MS], t,t-Muconic Acid (Creatinine correction) [mcg/g; LC/MS/MS] were added.			
1361U	Cumene Exposure Uptake Survey, Urine		
Scope of Analysis: Dimethylphenylcarbinol Creatinine was removed.			
1410U	Cyclohexanol, Urine		
Scope of Analysis: Cyclohexanol - Total Creatinine, Cyclohexanol (Creatinine correction) and Cyclohexanol were removed. Cyclohexanol - Total [mg/L; GC] was added.			
1550B	Dichloroethane, Blood		
Scope of Analysis: 1,1-Dichloroethane, 1,2-Dichloroethane Dichloroethane was removed. 1,1-Dichloroethane [mcg/mL; GC] and 1,2-Dichloroethane [mcg/mL; GC] were added.			
1550SP	Dichloroethane, Serum/Plasma		
Scope of Analysis: 1,1-Dichloroethane, 1,2-Dichloroethane Dichloroethane was removed. 1,1-Dichloroethane [mcg/mL; GC] and 1,2-Dichloroethane [mcg/mL; GC] were added.			
1550U	Dichloroethane, Urine		
Scope of Analysis: 1,1-Dichloroethane, 1,2-Dichloroethane Dichloroethane was removed. 1,1-Dichloroethane [mcg/mL; GC] and 1,2-Dichloroethane [mcg/mL; GC] were added.			
1930B	EP (FEP), Pediatric, Blood		
Specimen Requirements: 0.5 mL EDTA Blood Notes: Protection from light is required. Failure to submit a light protected sample will result in cancellation. All venipunctures should be performed using a trace metal free royal blue top tube. Light protection requirement was added.			

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code Changes	Unit Changes
2068B	Famotidine, Blood Specimen Requirements: 3 mL Blood Notes: Freeze and ship frozen. Frozen requirement was added.		
2068SP	Famotidine, Serum/Plasma Specimen Requirements: 3 mL Serum or Plasma Notes: Freeze and ship frozen. The use of serum separator tubes is not recommended. Frozen requirement was added.		
2291U	Hexanol, 1 and 2-, Urine Scope of Analysis: 1-Hexanol - Total, 2-Hexanol - Total 1-Hexanol, 2-Hexanol were removed. 1-Hexanol - Total [mg/L; GC], 2-Hexanol - Total [mg/L; GC] were added.		
5593U	Nortriptyline Confirmation, Urine • Nortriptyline Nortriptyline Units were changed.		ng/mL
9433U	Nortriptyline Screen, Urine • Nortriptyline Nortriptyline Units were changed.		ng/mL
0872U	Solvent Profile, Urine Scope of Analysis: Trichloroacetic Acid, Trichloroacetic Acid (Creatinine correction), Creatinine, Trichloroethanol - Total, o-Cresol, p-and/or m-Cresol, Phenol, Phenol (Creatinine correction), Hippuric Acid, Hippuric Acid (Creatinine correction), Mandelic Acid, Mandelic Acid (Creatinine correction), Phenylglyoxylic Acid, Phenylglyoxylic Acid (Creatinine correction), Methylhippuric Acid, Methylhippuric Acid (Creatinine correction), S-Phenylmercapturic Acid, S-Phenylmercapturic Acid (Creatinine correction), t,t-Muconic Acid, t,t-Muconic Acid (Creatinine correction) S-Phenylmercapturic Acid [mcg/L; LC/MS/MS; new CPT=82542], S-Phenylmercapturic Acid (Creatinine correction) [mcg/g; LC/MS/MS], t,t-Muconic Acid [mcg/L; LC/MS/MS], t,t-Muconic Acid (Creatinine correction) [mcg/g; LC/MS/MS] were added.		
4232B	Styrene, Blood • Styrene Styrene Units were changed.		mcg/mL
4232SP	Styrene, Serum/Plasma • Styrene Styrene Units were changed.		mcg/mL

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

DISCONTINUED TESTS – CATEGORY II

Test Code	Test Name	Alternative Test
4661B	Antidepressants Panel 2, Blood	4655B Antidepressants Panel 1, Blood
4661FL	Antidepressants Panel 2, Fluid	4655FL Antidepressants Panel 1, Fluid
4661SP	Antidepressants Panel 2, Serum/Plasma	4655SP Antidepressants Panel 1, Serum/Plasma
4661TI	Antidepressants Panel 2, Tissue	4655TI Antidepressants Panel 1, Tissue
4661U	Antidepressants Panel 2, Urine	4655U Antidepressants Panel 1, Urine
0454U	Aromatic Amines Panel, Urine	No alternate test available.
0456U	Aromatic Solvents Exposure Panel, Urine	0457U Aromatic Solvents Screen, Urine
0780B	Brucine, Blood	No alternate test available.
0780FL	Brucine, Fluid	No alternate test available.
0780SP	Brucine, Serum/Plasma	No alternate test available.
0780TI	Brucine, Tissue	No alternate test available.
0780U	Brucine, Urine	No alternate test available.
5639B	Brucine Confirmation, Blood	No alternate test available.
5639FL	Brucine Confirmation, Fluid	No alternate test available.
5639SP	Brucine Confirmation, Serum/Plasma	No alternate test available.
5639TI	Brucine Confirmation, Tissue	No alternate test available.
5639U	Brucine Confirmation, Urine	No alternate test available.
9119B	Brucine Screen, Blood	No alternate test available.
9119FL	Brucine Screen, Fluid	No alternate test available.
9119SP	Brucine Screen, Serum/Plasma	No alternate test available.
9119TI	Brucine Screen, Tissue	No alternate test available.
9119U	Brucine Screen, Urine	No alternate test available.
0790B	Buclizine, Blood	No alternate test available.
0790FL	Buclizine, Fluid	No alternate test available.
0790SP	Buclizine, Serum/Plasma	No alternate test available.
0790TI	Buclizine, Tissue	No alternate test available.
0790U	Buclizine, Urine	No alternate test available.
5464B	Buclizine Confirmation, Blood	No alternate test available.
5464FL	Buclizine Confirmation, Fluid	No alternate test available.
5464SP	Buclizine Confirmation, Serum/Plasma	No alternate test available.
5464TI	Buclizine Confirmation, Tissue	No alternate test available.
5464U	Buclizine Confirmation, Urine	No alternate test available.
9120B	Buclizine Screen, Blood	No alternate test available.
9120FL	Buclizine Screen, Fluid	No alternate test available.
9120SP	Buclizine Screen, Serum/Plasma	No alternate test available.
9120TI	Buclizine Screen, Tissue	No alternate test available.
9120U	Buclizine Screen, Urine	No alternate test available.

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

DISCONTINUED TESTS – CATEGORY II

Test Code	Test Name	Alternative Test
1001B	Carbon Monoxide Hemoglobin, Blood	1002B Carbon Monoxide Exposure Biouptake Screen, Blood
1001R	Carbon Monoxide Hemoglobin, RBCs	1002R Carbon Monoxide Exposure Biouptake Screen, RBCs
1090B	Chlormezanone, Blood	No alternate test available.
1090FL	Chlormezanone, Fluid	No alternate test available.
1090SP	Chlormezanone, Serum/Plasma	No alternate test available.
1090TI	Chlormezanone, Tissue	No alternate test available.
1090U	Chlormezanone, Urine	No alternate test available.
5481B	Chlormezanone Confirmation, Blood	No alternate test available.
5481FL	Chlormezanone Confirmation, Fluid	No alternate test available.
5481SP	Chlormezanone Confirmation, Serum/Plasma	No alternate test available.
5481TI	Chlormezanone Confirmation, Tissue	No alternate test available.
5481U	Chlormezanone Confirmation, Urine	No alternate test available.
9314B	Chlormezanone Screen, Blood	No alternate test available.
9314FL	Chlormezanone Screen, Fluid	No alternate test available.
9314SP	Chlormezanone Screen, Serum/Plasma	No alternate test available.
9314TI	Chlormezanone Screen, Tissue	No alternate test available.
9314U	Chlormezanone Screen, Urine	No alternate test available.
9125B	Dezocine Screen, Blood	No alternate test available.
9125SP	Dezocine Screen, Serum/Plasma	No alternate test available.
9125U	Dezocine Screen, Urine	No alternate test available.
5699B	Dezocine Confirmation, Blood	No alternate test available.
5699SP	Dezocine Confirmation, Serum/Plasma	No alternate test available.
5699U	Dezocine Confirmation, Urine	No alternate test available.
1930R	EP (FEP), Pediatric, RBCs	1930B EP (FEP), Pediatric, Blood
1931B	EP (FEP), Blood	1930B EP (FEP), Pediatric, Blood
1931R	EP (FEP), RBCs	1930B EP (FEP), Pediatric, Blood
2575B	Mazindol, Blood	No alternate test available.
2575FL	Mazindol, Fluid	No alternate test available.
2575SP	Mazindol, Serum/Plasma	No alternate test available.
2575TI	Mazindol, Tissue	No alternate test available.
2575U	Mazindol, Urine	No alternate test available.
5551B	Mazindol Confirmation, Blood	No alternate test available.
5551FL	Mazindol Confirmation, Fluid	No alternate test available.
5551SP	Mazindol Confirmation, Serum/Plasma	No alternate test available.
5551TI	Mazindol Confirmation, Tissue	No alternate test available.
5551U	Mazindol Confirmation, Urine	No alternate test available.

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

DISCONTINUED TESTS – CATEGORY II

Test Code	Test Name	Alternative Test
9194B	Mazindol Screen, Blood	No alternate test available.
9194FL	Mazindol Screen, Fluid	No alternate test available.
9194SP	Mazindol Screen, Serum/Plasma	No alternate test available.
9194TI	Mazindol Screen, Tissue	No alternate test available.
9194U	Mazindol Screen, Urine	No alternate test available.
2580B	Mebutamate, Blood	No alternate test available.
2580FL	Mebutamate, Fluid	No alternate test available.
2580SP	Mebutamate, Serum/Plasma	No alternate test available.
2580TI	Mebutamate, Tissue	No alternate test available.
2580U	Mebutamate, Urine	No alternate test available.
5552B	Mebutamate Confirmation, Blood	No alternate test available.
5552FL	Mebutamate Confirmation, Fluid	No alternate test available.
5552SP	Mebutamate Confirmation, Serum/Plasma	No alternate test available.
5552TI	Mebutamate Confirmation, Tissue	No alternate test available.
5552U	Mebutamate Confirmation, Urine	No alternate test available.
9195B	Mebutamate Screen, Blood	No alternate test available.
9195FL	Mebutamate Screen, Fluid	No alternate test available.
9195SP	Mebutamate Screen, Serum/Plasma	No alternate test available.
9195TI	Mebutamate Screen, Tissue	No alternate test available.
9195U	Mebutamate Screen, Urine	No alternate test available.
3445P	Pesticides/Insecticides Survey, Plasma	3445SP Pesticides/Insecticides Survey, Serum/Plasma
3447P	Pesticides/Insecticides Screen, Plasma	3447SP Pesticides/Insecticides Screen, Serum/Plasma
3451P	Pesticides/Insecticides Survey, Plasma	3451SP Pesticides/Insecticides Survey, Serum/Plasma
3453P	Pesticides/Insecticides Survey, Plasma	3453SP Pesticides/Insecticides Survey, Serum/Plasma
3619B	Phenols, Blood	No alternate test available.
3619SP	Phenols, Serum/Plasma	No alternate test available.
3619U	Phenols, Urine	No alternate test available.
3658FL	Phenothiazines Total Undifferentiated, Fluid	8680FL Phenothiazines Panel, Fluid
3658U	Phenothiazines Total Undifferentiated, Urine	8680U Phenothiazines Panel, Urine
3660FL	Phenothiazines (Total Undifferentiated) Screen, Fluid	9420FL Phenothiazines Screen, Fluid
3660U	Phenothiazines (Total Undifferentiated) Screen, Urine	9420U Phenothiazines Screen, Urine
5653FL	Phenothiazines (Total) Confirmation, Fluid	5545FL Phenothiazines Confirmation, Fluid
5653U	Phenothiazines (Total) Confirmation, Urine	5545U Phenothiazines Confirmation, Urine
4022B	Pseudoephedrine vs Ephedrine Differentiation, Blood	4023B Ephedrines Panel, Blood

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

DISCONTINUED TESTS – CATEGORY II

Test Code	Test Name	Alternative Test
4022FL	Pseudoephedrine vs Ephedrine Differentiation, Fluid	4023FL Ephedrines Panel, Fluid
4022ME	Pseudoephedrine vs Ephedrine Differentiation, Meconium	No alternate test available.
4022SP	Pseudoephedrine vs Ephedrine Differentiation, Serum/Plasma	4023SP Ephedrines Panel, Serum/Plasma
4022TI	Pseudoephedrine vs Ephedrine Differentiation, Tissue	4023TI Ephedrines Panel, Tissue
4022U	Pseudoephedrine vs Ephedrine Differentiation, Urine	4023U Ephedrines Panel, Urine
4209B	Stimulant Excitants Panel 1, Blood	4210B Stimulant Excitants Panel 2, Blood or 8600B Amphetamines Panel, Blood
4209SP	Stimulant Excitants Panel 1, Serum/Plasma	4210SP Stimulant Excitants Panel 2, Serum/Plasma or 8600SP Amphetamines Panel, Serum/Plasma

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
4655SP	Antidepressants Panel 1, Serum/Plasma <ul style="list-style-type: none"> • Nortriptyline • Desipramine 	<p>Nortriptyline is a metabolite of Amitriptyline and is also available as an independent therapeutic agent. When Amitriptyline is the administered drug: Usual therapeutic range for the total of Amitriptyline plus Nortriptyline: 80 - 250 ng/mL. When Nortriptyline is the administered drug: Usual therapeutic range: 50 - 150 ng/mL.</p> <p>Desipramine is a metabolite of Imipramine and is also available as an independent therapeutic agent. When Imipramine is the administered drug: Usual therapeutic range for the total of Imipramine plus Desipramine: 150 - 400 ng/mL. When Desipramine is the administered drug: Usual therapeutic range in outpatients on 100 to 200 mg Desipramine/day: 40 - 250 ng/mL.</p>
4655U	Antidepressants Panel 1, Urine <ul style="list-style-type: none"> • Nortriptyline • Desipramine 	<p>Nortriptyline is a metabolite of Amitriptyline and is also available as an independent therapeutic agent.</p> <p>Less than 5% of a given dose is typically excreted as unchanged drug in 24-hour post-dose urine.</p> <p>Desipramine is a metabolite of Imipramine and is also available as an independent therapeutic agent.</p> <p>24-hour post-dose urine typically contains less than 1% of an administered dose.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
5450B	Antidepressants Confirmation, Blood <ul style="list-style-type: none">NortriptylineDesipramineMirtazapine	<p>Nortriptyline is a metabolite of Amitriptyline and is also available as an independent therapeutic agent. When Amitriptyline is the administered drug: Usual therapeutic range for the total of Amitriptyline plus Nortriptyline: 80 - 250 ng/mL. When Nortriptyline is the administered drug: Usual therapeutic range: 50 - 150 ng/mL.</p> <p>Desipramine is a metabolite of Imipramine and is also available as an independent therapeutic agent. When Imipramine is the administered drug: Usual therapeutic range for the total of Imipramine plus Desipramine: 150 - 400 ng/mL. When Desipramine is the administered drug: Usual therapeutic range in outpatients on 100 to 200 mg Desipramine/day: 40 - 250 ng/mL.</p> <p>Steady-state peak (0.7 to 4.8 hours post-dose) and trough plasma concentrations following a daily regimen: 15 mg/day: 27 - 51 ng/mL peak; 4.3 - 12 ng/mL trough 30 mg/day: 56 - 104 ng/mL peak; 11 - 25 ng/mL trough 45 mg/day: 84 - 142 ng/mL peak; 17 - 39 ng/mL trough 60 mg/day: 117 - 199 ng/mL peak; 24 - 52 ng/mL trough 75 mg/day: 137 - 225 ng/mL peak; 28 - 64 ng/mL trough</p> <p>Elimination half-life: 20 to 40 hours.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
5450SP	Antidepressants Confirmation, Serum/Plasma <ul style="list-style-type: none"> • Nortriptyline • Desipramine • Mirtazapine 	<p>Nortriptyline is a metabolite of Amitriptyline and is also available as an independent therapeutic agent. When Amitriptyline is the administered drug: Usual therapeutic range for the total of Amitriptyline plus Nortriptyline: 80 - 250 ng/mL. When Nortriptyline is the administered drug: Usual therapeutic range: 50 - 150 ng/mL.</p> <p>Desipramine is a metabolite of Imipramine and is also available as an independent therapeutic agent. When Imipramine is the administered drug: Usual therapeutic range for the total of Imipramine plus Desipramine: 150 - 400 ng/mL. When Desipramine is the administered drug: Usual therapeutic range in outpatients on 100 to 200 mg Desipramine/day: 40 - 250 ng/mL.</p> <p>Steady-state peak (0.7 to 4.8 hours post-dose) and trough plasma concentrations following a daily regimen: 15 mg/day: 27 - 51 ng/mL peak; 4.3 - 12 ng/mL trough 30 mg/day: 56 - 104 ng/mL peak; 11 - 25 ng/mL trough 45 mg/day: 84 - 142 ng/mL peak; 17 - 39 ng/mL trough 60 mg/day: 117 - 199 ng/mL peak; 24 - 52 ng/mL trough 75 mg/day: 137 - 225 ng/mL peak; 28 - 64 ng/mL trough</p> <p>Elimination half-life: 20 to 40 hours.</p>
5450U	Antidepressants Confirmation, Urine <ul style="list-style-type: none"> • Nortriptyline • Desipramine 	<p>Nortriptyline is a metabolite of Amitriptyline and is also available as an independent therapeutic agent.</p> <p>Less than 5% of a given dose is typically excreted as unchanged drug in 24-hour post-dose urine.</p> <p>Desipramine is a metabolite of Imipramine and is also available as an independent therapeutic agent.</p> <p>24-hour post-dose urine typically contains less than 1% of an administered dose.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
8700B	Antidepressants Panel, Blood <ul style="list-style-type: none"> • Nortriptyline • Desipramine • Venlafaxine • Mirtazapine 	<p>Nortriptyline is a metabolite of Amitriptyline is also available as an independent therapeutic agent. When Amitriptyline is the administered drug: Usual therapeutic range for the total of Amitriptyline plus Nortriptyline: 80 - 250 ng/mL. When Nortriptyline is the administered drug: Usual therapeutic range: 50 - 150 ng/mL.</p> <p>Desipramine is a metabolite of Imipramine and is also available as an independent therapeutic agent. When Imipramine is the administered drug: Usual therapeutic range for the total of Imipramine plus Desipramine: 150 - 400 ng/mL. When Desipramine is the administered drug: Usual therapeutic range in outpatients on 100 to 200 mg Desipramine/day: 40 - 250 ng/mL.</p> <p>Steady-state peak plasma concentrations following a daily regimen occur at approximately 2 hours post-dose for Venlafaxine: 35 - 79 ng/mL (75 mg/day), 93 - 334 ng/mL (150 mg/day), 68 - 265 ng/mL (225 mg/day), 196 - 597 ng/mL (450 mg/day).</p> <p>Steady-state trough plasma concentrations following a 150 mg per day regimen: 0 - 141 ng/mL.</p> <p>Steady-state peak (0.7 to 4.8 hours post-dose) and trough plasma concentrations following a daily regimen: 15 mg/day: 27 - 51 ng/mL peak; 4.3 - 12 ng/mL trough 30 mg/day: 56 - 104 ng/mL peak; 11 - 25 ng/mL trough 45 mg/day: 84 - 142 ng/mL peak; 17 - 39 ng/mL trough 60 mg/day: 117 - 199 ng/mL peak; 24 - 52 ng/mL trough 75 mg/day: 137 - 225 ng/mL peak; 28 - 64 ng/mL trough</p> <p>Elimination half-life: 20 to 40 hours.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
8700SP	Antidepressants Panel, Serum/Plasma <ul style="list-style-type: none"> • Nortriptyline • Desipramine • Venlafaxine • Mirtazapine 	<p>Nortriptyline is a metabolite of Amitriptyline and is also available as an independent therapeutic agent. When Amitriptyline is the administered drug: Usual therapeutic range for the total of Amitriptyline plus Nortriptyline: 80 - 250 ng/mL. When Nortriptyline is the administered drug: Usual therapeutic range: 50 - 150 ng/mL.</p> <p>Desipramine is a metabolite of Imipramine and is also available as an independent therapeutic agent. When Imipramine is the administered drug: Usual therapeutic range for the total of Imipramine plus Desipramine: 150 - 400 ng/mL. When Desipramine is the administered drug: Usual therapeutic range in outpatients on 100 to 200 mg Desipramine/day: 40 - 250 ng/mL.</p> <p>Steady-state peak plasma concentrations following a daily regimen occur at approximately 2 hours post-dose for Venlafaxine: 35 - 79 ng/mL (75 mg/day), 93 - 334 ng/mL (150 mg/day), 68 - 265 ng/mL (225 mg/day), 196 - 597 ng/mL (450 mg/day).</p> <p>Steady-state trough plasma concentrations following a 150 mg per day regimen: 0 - 141 ng/mL.</p> <p>Steady-state peak (0.7 to 4.8 hours post-dose) and trough plasma concentrations following a daily regimen: 15 mg/day: 27 - 51 ng/mL peak; 4.3 - 12 ng/mL trough 30 mg/day: 56 - 104 ng/mL peak; 11 - 25 ng/mL trough 45 mg/day: 84 - 142 ng/mL peak; 17 - 39 ng/mL trough 60 mg/day: 117 - 199 ng/mL peak; 24 - 52 ng/mL trough 75 mg/day: 137 - 225 ng/mL peak; 28 - 64 ng/mL trough</p> <p>Elimination half-life: 20 to 40 hours.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
9431SP	Antidepressants Screen, Serum/Plasma <ul style="list-style-type: none"> • Nortriptyline • Desipramine • Mirtazapine 	<p>Nortriptyline is a metabolite of Amitriptyline and is also available as an independent therapeutic agent. When Amitriptyline is the administered drug: Usual therapeutic range for the total of Amitriptyline plus Nortriptyline: 80 - 250 ng/mL. When Nortriptyline is the administered drug: Usual therapeutic range: 50 - 150 ng/mL.</p> <p>Desipramine is a metabolite of Imipramine and is also available as an independent therapeutic agent. When Imipramine is the administered drug: Usual therapeutic range for the total of Imipramine plus Desipramine: 150 - 400 ng/mL. When Desipramine is the administered drug: Usual therapeutic range in outpatients on 100 to 200 mg Desipramine/day: 40 - 250 ng/mL.</p> <p>Steady-state peak (0.7 to 4.8 hours post-dose) and trough plasma concentrations following a daily regimen: 15 mg/day: 27 - 51 ng/mL peak; 4.3 - 12 ng/mL trough 30 mg/day: 56 - 104 ng/mL peak; 11 - 25 ng/mL trough 45 mg/day: 84 - 142 ng/mL peak; 17 - 39 ng/mL trough 60 mg/day: 117 - 199 ng/mL peak; 24 - 52 ng/mL trough 75 mg/day: 137 - 225 ng/mL peak; 28 - 64 ng/mL trough</p> <p>Elimination half-life: 20 to 40 hours.</p>
9431U	Antidepressants Screen, Urine <ul style="list-style-type: none"> • Nortriptyline • Desipramine 	<p>Nortriptyline is a metabolite of Amitriptyline and is also available as an independent therapeutic agent.</p> <p>Less than 5% of a given dose is typically excreted as unchanged drug in 24-hour post-dose urine.</p> <p>Desipramine is a metabolite of Imipramine and is also available as an independent therapeutic agent.</p> <p>24-hour post-dose urine typically contains less than 1% of an administered dose.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
0408B	Antihistamines Panel, Blood <ul style="list-style-type: none">Diphenhydramine	Usual antihistaminic hypnotic range: 100 - 1000 ng/mL. Toxicity reported at greater than 1000 ng/mL. Lidocaine interferes with diphenhydramine in this analysis. The presence of lidocaine will adversely affect the quantitation of diphenhydramine. If lidocaine is a potential interferent in this case, call the laboratory for alternate quantitative procedures.
0408SP	Antihistamines Panel, Serum/Plasma <ul style="list-style-type: none">Diphenhydramine	Usual antihistaminic hypnotic range: 100 - 1000 ng/mL. Toxicity reported at greater than 1000 ng/mL. Lidocaine interferes with diphenhydramine in this analysis. The presence of lidocaine will adversely affect the quantitation of diphenhydramine. If lidocaine is a potential interferent in this case, call the laboratory for alternate quantitative procedures.
0408U	Antihistamines Panel, Urine <ul style="list-style-type: none">Diphenhydramine	Lidocaine interferes with diphenhydramine in this analysis. The presence of lidocaine will adversely affect the quantitation of diphenhydramine. If lidocaine is a potential interferent in this case, call the laboratory for alternate quantitative procedures.
0785B	Aromatic Solvents Exposure Panel, Blood <ul style="list-style-type: none">Toluene	Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.
0785SP	Aromatic Solvents Exposure Panel, Serum/Plasma <ul style="list-style-type: none">Toluene	Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
0457U	Aromatic Solvents Profile, Urine <ul style="list-style-type: none"> • o-Cresol • Hippuric Acid (Creatinine corrected) • Mandelic Acid (Creatinine corrected) • p-and/or m-Cresol • Phenylglyoxylic Acid (Creatinine corrected) • Phenol (Creatinine corrected) • S-Phenylmercapturic Acid (Creatinine corrected) • t,t-Muconic Acid (Creatinine corrected) 	<p>Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 0.5 mg o-Cresol/L urine measured in an end of shift specimen.</p> <p>Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 1.6 g Hippuric Acid/g Creatinine measured in an end of shift specimen.</p> <p>Biological Exposure Index (ACGIH) for monitoring exposure to Ethylbenzene: 1.5 g Mandelic Acid/g Creatinine measured in an end of shift at end of workweek specimen. For monitoring exposure to Styrene: Mandelic Acid plus Phenylglyoxylic Acid: 0.4 g/g Creatinine measured in an end of shift specimen.</p> <p>Normal: 20 - 200 mg p-Cresol/L.</p> <p>Biological Exposure Index (ACGIH) for monitoring exposure to Styrene: Mandelic Acid plus Phenylglyoxylic Acid: 0.4 g/g Creatinine measured in an end of shift specimen.</p> <p>Biological Exposure Index (ACGIH): 250 mg Phenol/g Creatinine measured in an end of shift urine.</p> <p>Biological Exposure Index (ACGIH) for monitoring exposure to Benzene: 25 mcg S-Phenylmercapturic Acid/g Creatinine measured in an end of shift specimen.</p> <p>Biological Exposure Index (ACGIH) for monitoring exposure to Benzene: 500 mcg t,t-Muconic Acid/g Creatinine measured in an end of shift specimen.</p>
8620B	Barbiturates Panel, Blood <ul style="list-style-type: none"> • Phenobarbital 	<p>Anticonvulsant range (serum/plasma): 10 - 30 mcg/mL. Blood to plasma ratio: 0.81.</p>
8620SP	Barbiturates Panel, Serum/Plasma <ul style="list-style-type: none"> • Phenobarbital 	<p>Anticonvulsant range: 10 - 30 mcg/mL.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
5225B	Barbiturates Confirmation, Blood <ul style="list-style-type: none"> Phenobarbital 	Anticonvulsant range (serum/plasma): 10 - 30 mcg/mL. Blood to plasma ratio: 0.81.
5225SP	Barbiturates Confirmation, Serum/Plasma <ul style="list-style-type: none"> Phenobarbital 	Anticonvulsant range: 10 - 30 mcg/mL.
5651B	Barbiturates Confirmation, Blood <ul style="list-style-type: none"> Phenobarbital 	Anticonvulsant range (serum/plasma): 10 - 30 mcg/mL. Blood to plasma ratio: 0.81.
5651SP	Barbiturates Confirmation, Serum/Plasma <ul style="list-style-type: none"> Phenobarbital 	Anticonvulsant range: 10 - 30 mcg/mL.
0680B	Bismuth, Blood <ul style="list-style-type: none"> Bismuth 	Reference range: 10 - 50 mcg/L. Toxicity is generally associated with concentrations exceeding 100 mcg/L.
1042SP	Cesium, Serum/Plasma <ul style="list-style-type: none"> Cesium 	Average in normal population: 5.1 mcg/L Plasma (+/- 0.2 mcg/L)
2215B	Chlorinated Solvents, Blood <ul style="list-style-type: none"> Perchloroethylene 	Biological Exposure Index (ACGIH): 0.5 mcg/mL in blood specimen collected prior to last shift of workweek.
2215SP	Chlorinated Solvents, Serum/Plasma <ul style="list-style-type: none"> Perchloroethylene 	Biological Exposure Index (ACGIH): 0.5 mcg/mL in blood specimen collected prior to last shift of workweek.
2216B	Chlorinated Hydrocarbons, Blood <ul style="list-style-type: none"> Perchloroethylene 	Biological Exposure Index (ACGIH): 0.5 mcg/mL in blood specimen collected prior to last shift of workweek.
1330SP	Copper, Serum/Plasma <ul style="list-style-type: none"> Copper 	Normal Adult: 70 - 155 mcg/dL Birth to 6 months: 20 - 70 mcg/dL Pregnant: 118 - 300 mcg/ dL
1350U	Cresols, Urine <ul style="list-style-type: none"> o-Cresol 	Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 0.5 mg o-Cresol/L urine measured in an end of shift specimen.
1410U	Cyclohexanol, Urine <ul style="list-style-type: none"> Cyclohexanol - Total 	Concentrations range from 0.12 - 8.2 mg/L at the end of a shift with air concentrations of 5 to 211 ppm.
1550B	Dichloroethane, Blood <ul style="list-style-type: none"> 1,2-Dichloroethane 	No reference data available.
1550SP	Dichloroethane, Serum/Plasma <ul style="list-style-type: none"> 1,2-Dichloroethane 	No reference data available.

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
1550U	Dichloroethane, Urine • 1,2-Dichloroethane	No reference data available.
1693B	Dimethyltryptamine, Blood • Dimethyltryptamine	Peak plasma concentrations ranged from 12 - 26 ng/mL (mean, 16 mg/mL) at 1.5 hours after a 29 mg oral dose.
1693SP	Dimethyltryptamine, Serum/Plasma • Dimethyltryptamine	Peak plasma concentrations ranged from 12 - 26 ng/mL (mean, 16 mg/mL) at 1.5 hours after a 29 mg oral dose.
1760B	Diphenhydramine, Blood • Diphenhydramine	Usual antihistaminic hypnotic range: 100 - 1000 ng/mL. Toxicity reported at greater than 1000 ng/mL. Lidocaine interferes with diphenhydramine in this analysis. The presence of lidocaine will adversely affect the quantitation of diphenhydramine. If lidocaine is a potential interferent in this case, call the laboratory for alternate quantitative procedures.
1760SP	Diphenhydramine, Serum/Plasma • Diphenhydramine	Usual antihistaminic hypnotic range: 100 - 1000 ng/mL. Toxicity reported at greater than 1000 ng/mL. Lidocaine interferes with diphenhydramine in this analysis. The presence of lidocaine will adversely affect the quantitation of diphenhydramine. If lidocaine is a potential interferent in this case, call the laboratory for alternate quantitative procedures.
1760U	Diphenhydramine, Urine • Diphenhydramine	Lidocaine interferes with diphenhydramine in this analysis. The presence of lidocaine will adversely affect the quantitation of diphenhydramine. If lidocaine is a potential interferent in this case, call the laboratory for alternate quantitative procedures.
1808B	Donnatal, Blood • Phenobarbital	Anticonvulsant range (serum/plasma): 10 - 30 mcg/mL. Blood to plasma ratio: 0.81.
1808SP	Donnatal, Serum/Plasma • Phenobarbital	Anticonvulsant range: 10 - 30 mcg/mL.
1930B	EP (FEP), Pediatric, Blood • EP	EP is no longer recommended as a screening test for Lead exposure in children. Previously, follow-up monitoring of Blood Lead concentration was recommended when EP was 35 mcg/dL or greater.

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
1959R	Ethambutol, RBCs • Ethambutol	No reference data available.
2154SP	Ganciclovir, Serum/Plasma • Ganciclovir	Plasma concentrations after 1-hour I.V. infusion of 5 mg/kg were 9.46 +/- 2.02 mcg/mL at 1 hour post-dose and 0.56 +/- 0.66 mcg/mL at 11 hours post-dose. Peak plasma concentrations following chronic oral administration of 1000 mg three times daily ranged from 0.95 - 1.40 mcg/mL.
2160B	Glutethimide, Blood • Glutethimide	Usual sedative-hypnotic range: 2 - 6 mcg/mL.
2160SP	Glutethimide, Serum/Plasma • Glutethimide	Usual sedative-hypnotic range: 2 - 6 mcg/mL.
2220B	Haloperidol, Blood • Haloperidol	Steady-state antipsychotic plasma concentration during daily regimen of 1 to 90 mg/day: 0.5 - 120 ng/mL (mean, 6 ng/mL). Blood to plasma ratio: 0.79. Clozapine and zolpidem interfere with haloperidol in this analysis. The presence of clozapine or zolpidem will adversely affect the quantitation of haloperidol. If clozapine or zolpidem are potential interferents in this case, call the laboratory for alternate quantitative procedures.
2220SP	Haloperidol, Serum/Plasma • Haloperidol	Steady-state antipsychotic plasma concentration during daily regimen of 1 to 90 mg/day: 0.5 - 120 ng/mL (mean, 6 ng/mL). Clozapine and zolpidem interfere with haloperidol in this analysis. The presence of clozapine or zolpidem will adversely affect the quantitation of haloperidol. If clozapine or zolpidem are potential interferents in this case, call the laboratory for alternate quantitative procedures.

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
5527B	Haloperidol Confirmation, Blood <ul style="list-style-type: none"> Haloperidol 	<p>Steady-state antipsychotic plasma concentration during daily regimen of 1 to 90 mg/day: 0.5 - 120 ng/mL (mean, 6 ng/mL). Blood to plasma ratio: 0.79.</p> <p>Clozapine and zolpidem interfere with haloperidol in this analysis. The presence of clozapine or zolpidem will adversely affect the quantitation of haloperidol. If clozapine or zolpidem are potential interferents in this case, call the laboratory for alternate quantitative procedures.</p>
5527SP	Haloperidol Confirmation, Serum/Plasma <ul style="list-style-type: none"> Haloperidol 	<p>Steady-state antipsychotic plasma concentration during daily regimen of 1 to 90 mg/day: 0.5 - 120 ng/mL (mean, 6 ng/mL).</p> <p>Clozapine and zolpidem interfere with haloperidol in this analysis. The presence of clozapine or zolpidem will adversely affect the quantitation of haloperidol. If clozapine or zolpidem are potential interferents in this case, call the laboratory for alternate quantitative procedures.</p>
9182B	Haloperidol Screen, Blood <ul style="list-style-type: none"> Haloperidol 	<p>Steady-state antipsychotic plasma concentration during daily regimen of 1 to 90 mg/day: 0.5 - 120 ng/mL (mean, 6 ng/mL). Blood to plasma ratio: 0.79.</p> <p>Clozapine and zolpidem interfere with haloperidol in this analysis. The presence of clozapine or zolpidem will adversely affect the quantitation of haloperidol. If clozapine or zolpidem are potential interferents in this case, call the laboratory for alternate quantitative procedures.</p>
9182SP	Haloperidol Screen, Serum/Plasma <ul style="list-style-type: none"> Haloperidol 	<p>Steady-state antipsychotic plasma concentration during daily regimen of 1 to 90 mg/day: 0.5 - 120 ng/mL (mean, 6 ng/mL).</p> <p>Clozapine and zolpidem interfere with haloperidol in this analysis. The presence of clozapine or zolpidem will adversely affect the quantitation of haloperidol. If clozapine or zolpidem are potential interferents in this case, call the laboratory for alternate quantitative procedures.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
2232B	Heavy Metals Panel, Blood <ul style="list-style-type: none"> Mercury 	<p>Biological Exposure Index (ACGIH): 15 mcg Total Inorganic Mercury/L in blood collected at end of shift at end of workweek.</p> <p>Various States require that Blood Mercury levels above certain cutoffs must be reported to the State in which the patient resides. Please contact us if you need assistance in supplying your State with the required information.</p>
2241U	Heavy Metals Panel, Urine <ul style="list-style-type: none"> Lead (Creatinine corrected) 	<p>Various States require that levels above certain cutoffs must be reported to the State in which the patient resides. Please contact us if you need assistance in supplying your State with the required information.</p>
2242U	Heavy Metals Panel, Urine <ul style="list-style-type: none"> Tellurium 	<p>Less than 1 mcg/L urine in non-occupationally exposed individuals.</p>
2291U	Hexanol, 1 and 2-, Urine <ul style="list-style-type: none"> 2-Hexanol - Total 	<p>Average 0.2 mg/L in workers exposed to n-Hexane air concentrations of 182 mg/cubic meter.</p>
2300U	Hippuric Acid, Urine <ul style="list-style-type: none"> Hippuric Acid (Creatinine corrected) 	<p>Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 1.6 g Hippuric Acid/g Creatinine measured in an end of shift specimen.</p>
2306U	Hippuric Acid and Methylhippuric Acid, Urine <ul style="list-style-type: none"> Hippuric Acid (Creatinine corrected) 	<p>Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 1.6 g Hippuric Acid/g Creatinine measured in an end of shift specimen.</p>
2321B	Hydrocarbon and Oxygenated Volatiles Panel, Blood <ul style="list-style-type: none"> Toluene 	<p>Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.</p>
2321SP	Hydrocarbon and Oxygenated Volatiles Panel, Serum/Plasma <ul style="list-style-type: none"> Toluene 	<p>Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.</p>
2340B	Hydrocodone, Blood <ul style="list-style-type: none"> Hydrocodone 	<p>Following a single 10 mg oral hydrocodone bitartrate dose: Up to 32 ng/mL at 1.5 hours post-dose.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
2340SP	Hydrocodone, Serum/Plasma • Hydrocodone	Following a single 10 mg oral hydrocodone bitartrate dose: Up to 32 ng/mL at 1.5 hours post-dose.
2417B	Inhalant Intoxicants Survey, Blood • Toluene	Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.
2408B	Inhalants Panel, Blood • Toluene	Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.
2415B	Inhalants Panel, Blood • Toluene	Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.
2415SP	Inhalants Panel, Serum/Plasma • Toluene	Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.
2411B	Inhalants Panel, Solvents, Blood • Toluene	Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.
2411SP	Inhalants Panel, Solvents, Serum/Plasma • Toluene	Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.
2413B	Inhalants Panel, Solvents and Gases, Blood • Toluene	Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.
2510B	Lidocaine, Blood • Lidocaine	Reported antiarrhythmic range: 2 - 5 mcg/mL. Diphenhydramine interferes with lidocaine in this analysis. The presence of diphenhydramine will adversely affect the quantitation of lidocaine. If diphenhydramine is a potential interferent in this case, call the laboratory for alternate quantitative procedures.

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
2510SP	Lidocaine, Serum/Plasma <ul style="list-style-type: none">Lidocaine	Reported antiarrhythmic range: 2 - 5 mcg/mL. Diphenhydramine interferes with lidocaine in this analysis. The presence of diphenhydramine will adversely affect the quantitation of lidocaine. If diphenhydramine is a potential interferent in this case, call the laboratory for alternate quantitative procedures.
2510U	Lidocaine, Urine <ul style="list-style-type: none">Lidocaine	Diphenhydramine interferes with lidocaine in this analysis. The presence of diphenhydramine will adversely affect the quantitation of lidocaine. If diphenhydramine is a potential interferent in this case, call the laboratory for alternate quantitative procedures.
2512B	Lidocaine and Metabolite (MEGX), Blood <ul style="list-style-type: none">Lidocaine	Reported antiarrhythmic range: 2 - 5 mcg/mL. Diphenhydramine interferes with lidocaine in this analysis. The presence of diphenhydramine will adversely affect the quantitation of lidocaine. If diphenhydramine is a potential interferent in this case, call the laboratory for alternate quantitative procedures.
2512SP	Lidocaine and Metabolite (MEGX), Serum/Plasma <ul style="list-style-type: none">Lidocaine	Reported antiarrhythmic range: 2 - 5 mcg/mL. Diphenhydramine interferes with lidocaine in this analysis. The presence of diphenhydramine will adversely affect the quantitation of lidocaine. If diphenhydramine is a potential interferent in this case, call the laboratory for alternate quantitative procedures.
2512U	Lidocaine and Metabolite (MEGX), Urine <ul style="list-style-type: none">Lidocaine	Diphenhydramine interferes with lidocaine in this analysis. The presence of diphenhydramine will adversely affect the quantitation of lidocaine. If diphenhydramine is a potential interferent in this case, call the laboratory for alternate quantitative procedures.

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
2557U	Mandelic Acid, Urine <ul style="list-style-type: none"> Mandelic Acid (Creatinine corrected) 	Biological Exposure Index (ACGIH) for monitoring exposure to Ethylbenzene: 1.5 g Mandelic Acid/g Creatinine measured in an end of shift at end of workweek specimen. For monitoring exposure to Styrene: Mandelic Acid plus Phenylglyoxylic Acid: 0.4 g/g Creatinine measured in an end of shift specimen.
2620B	Mephenytoin and Metabolite, Blood <ul style="list-style-type: none"> Normephenytoin 	Suggested therapeutic range for combined plasma Mephenytoin and Normephenytoin concentrations during chronic therapy: 25 - 40 mcg/mL.
2620SP	Mephenytoin and Metabolite, Serum/Plasma <ul style="list-style-type: none"> Normephenytoin 	Suggested therapeutic range for combined plasma Mephenytoin and Normephenytoin concentrations during chronic therapy: 25 - 40 mcg/mL.
2630B	Mephobarbital and Metabolite, Blood <ul style="list-style-type: none"> Phenobarbital 	Anticonvulsant range (serum/plasma): 10 - 30 mcg/mL. Blood to plasma ratio: 0.81.
2630SP	Mephobarbital and Metabolite, Serum/Plasma <ul style="list-style-type: none"> Phenobarbital 	Anticonvulsant range: 10 - 30 mcg/mL.
2670B	Mercury, Blood <ul style="list-style-type: none"> Mercury 	Biological Exposure Index (ACGIH): 15 mcg Total Inorganic Mercury/L in blood collected at end of shift at end of workweek. Various States require that Blood Mercury levels above certain cutoffs must be reported to the State in which the patient resides. Please contact us if you need assistance in supplying your State with the required information.
2675B	Mercury Exposure Survey, Blood <ul style="list-style-type: none"> Mercury 	Biological Exposure Index (ACGIH): 15 mcg Total Inorganic Mercury/L in blood collected at end of shift at end of workweek. Various States require that Blood Mercury levels above certain cutoffs must be reported to the State in which the patient resides. Please contact us if you need assistance in supplying your State with the required information.

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
2693B	Metals/Metalloids Acute Poisoning Panel, Blood <ul style="list-style-type: none"> • Bismuth • Mercury 	<p>Reference range: 10 - 50 mcg/L. Toxicity is generally associated with concentrations exceeding 100 mcg/L.</p> <p>Biological Exposure Index (ACGIH): 15 mcg Total Inorganic Mercury/L in blood collected at end of shift at end of workweek.</p> <p>Various States require that Blood Mercury levels above certain cutoffs must be reported to the State in which the patient resides. Please contact us if you need assistance in supplying your State with the required information.</p>
2697B	Metals Acute Poisoning Panel, Blood <ul style="list-style-type: none"> • Bismuth • Mercury 	<p>Reference range: 10 - 50 mcg/L. Toxicity is generally associated with concentrations exceeding 100 mcg/L.</p> <p>Biological Exposure Index (ACGIH): 15 mcg Total Inorganic Mercury/L in blood collected at end of shift at end of workweek.</p> <p>Various States require that Blood Mercury levels above certain cutoffs must be reported to the State in which the patient resides. Please contact us if you need assistance in supplying your State with the required information.</p>
6311B	Metals/Metalloids Panel, Blood <ul style="list-style-type: none"> • Mercury 	<p>Biological Exposure Index (ACGIH): 15 mcg Total Inorganic Mercury/L in blood collected at end of shift at end of workweek.</p> <p>Various States require that Blood Mercury levels above certain cutoffs must be reported to the State in which the patient resides. Please contact us if you need assistance in supplying your State with the required information.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
2661B	Metals/Metalloids Panel 1, Blood <ul style="list-style-type: none"> Mercury 	<p>Biological Exposure Index (ACGIH): 15 mcg Total Inorganic Mercury/L in blood collected at end of shift at end of workweek.</p> <p>Various States require that Blood Mercury levels above certain cutoffs must be reported to the State in which the patient resides. Please contact us if you need assistance in supplying your State with the required information.</p>
2663B	Metals/Metalloids Panel 3, Blood <ul style="list-style-type: none"> Mercury 	<p>Biological Exposure Index (ACGIH): 15 mcg Total Inorganic Mercury/L in blood collected at end of shift at end of workweek.</p> <p>Various States require that Blood Mercury levels above certain cutoffs must be reported to the State in which the patient resides. Please contact us if you need assistance in supplying your State with the required information.</p>
2584U	Methylenedioxyamphetamine, Urine <ul style="list-style-type: none"> Methylenedioxyamphetamine 	No reference data available.
9292U	Methylenedioxyamphetamine Screen, Urine <ul style="list-style-type: none"> Methylenedioxyamphetamine 	No reference data available.
9293U	Methylenedioxymethamphetamine and Metabolite Screen, Urine <ul style="list-style-type: none"> Methylenedioxyamphetamine 	No reference data available.
3020B	Methylphenidate and Metabolite, Blood <ul style="list-style-type: none"> Ritalinic Acid 	Plasma concentrations 3 to 6 hours post-dose in children given a 10 to 15 mg oral dose of Methylphenidate: 80 - 250 ng Ritalinic Acid/mL.
3020SP	Methylphenidate and Metabolite, Serum/Plasma <ul style="list-style-type: none"> Ritalinic Acid 	Plasma concentrations 3 to 6 hours post-dose in children given a 10 to 15 mg oral dose of Methylphenidate: 80 - 250 ng Ritalinic Acid/mL.
8673B	Morphine - Free and Total, Blood <ul style="list-style-type: none"> Morphine - Total 	<p>Total Morphine concentrations include unconjugated Morphine plus conjugated metabolites (Morphine-3-Glucuronide and Morphine-6-Glucuronide).</p> <p>Total Morphine concentrations should be equal to or greater than corresponding free Morphine concentrations. However, due to analytical variation, a total concentration may be nominally lower than the corresponding free concentration.</p>

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
8673SP	Morphine - Free and Total, Serum/Plasma <ul style="list-style-type: none"> Morphine - Total 	<p>Total Morphine concentrations include unconjugated Morphine plus conjugated metabolites (Morphine-3-Glucuronide and Morphine-6-Glucuronide).</p> <p>Total Morphine concentrations should be equal to or greater than corresponding free Morphine concentrations. However, due to analytical variation, a total concentration may be nominally lower than the corresponding free concentration.</p>
8672B	Morphine - Total (Conjugated and Unconjugated), Blood <ul style="list-style-type: none"> Morphine - Total 	<p>Total Morphine concentrations include unconjugated Morphine plus conjugated metabolites (Morphine-3-Glucuronide and Morphine-6-Glucuronide). Typically the concentrations of the conjugated metabolites in the blood exceed that of the unconjugated (or free) drug.</p>
8672SP	Morphine - Total (Conjugated and Unconjugated), Serum/Plasma <ul style="list-style-type: none"> Morphine - Total 	<p>Total Morphine concentrations include unconjugated Morphine plus conjugated metabolites (Morphine-3-Glucuronide and Morphine-6-Glucuronide). Typically the concentrations of the conjugated metabolites in the blood exceed that of the unconjugated (or free) drug.</p>
8367B	Natural Gas and Inhalants Survey, Blood <ul style="list-style-type: none"> Toluene 	<p>Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.</p>
3148B	Nicotine and Metabolite, Blood <ul style="list-style-type: none"> Nicotine 	<p>Observed concentrations in habitual smokers: 3 - 63 ng Nicotine/mL.</p>
3148SP	Nicotine and Metabolite, Serum/Plasma <ul style="list-style-type: none"> Nicotine 	<p>Observed concentrations in habitual smokers: 3 - 63 ng Nicotine/mL.</p>
1352U	o-Cresol, Urine <ul style="list-style-type: none"> o-Cresol 	<p>Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 0.5 mg o-Cresol/L urine measured in an end of shift specimen.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
8660B	Opiates - Free (Unconjugated), Blood <ul style="list-style-type: none">Oxycodone - Free	<p>Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL.</p> <p>Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL.</p> <p>Mean peak plasma concentrations following a single dose of a 40 to 80 mg controlled-release Oxycodone preparation: 39 - 100 ng/mL.</p> <p>Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.</p>
8660SP	Opiates - Free (Unconjugated), Serum/Plasma <ul style="list-style-type: none">Oxycodone - Free	<p>Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL.</p> <p>Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL.</p> <p>Mean peak plasma concentrations following a single dose of a 40 to 80 mg controlled-release Oxycodone preparation: 39 - 100 ng/mL.</p> <p>Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
5723B	Opiates - Free (Unconjugated) Confirmation, Blood <ul style="list-style-type: none"> • Oxycodone - Free 	<p>Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL.</p> <p>Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL.</p> <p>Mean peak plasma concentrations following a single dose of a 40 to 80 mg controlled-release Oxycodone preparation: 39 - 100 ng/mL.</p> <p>Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.</p>
5723SP	Opiates - Free (Unconjugated) Confirmation, Serum/Plasma <ul style="list-style-type: none"> • Oxycodone - Free 	<p>Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL.</p> <p>Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL.</p> <p>Mean peak plasma concentrations following a single dose of a 40 to 80 mg controlled-release Oxycodone preparation: 39 - 100 ng/mL.</p> <p>Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
5645B	Opiates - Free (Unconjugated) Confirmation, Blood <ul style="list-style-type: none"> • Oxycodone - Free 	<p>Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL.</p> <p>Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL.</p> <p>Mean peak plasma concentrations following a single dose of a 40 to 80 mg controlled-release Oxycodone preparation: 39 - 100 ng/mL.</p> <p>Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.</p>
5645SP	Opiates - Free (Unconjugated) Confirmation, Serum/Plasma <ul style="list-style-type: none"> • Oxycodone - Free 	<p>Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL.</p> <p>Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL.</p> <p>Mean peak plasma concentrations following a single dose of a 40 to 80 mg controlled-release Oxycodone preparation: 39 - 100 ng/mL.</p> <p>Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
8670R	Opiates - Total (Conjugated/Unconjugated), RBCs <ul style="list-style-type: none"> • Morphine - Total 	Total Morphine concentrations include unconjugated Morphine plus conjugated metabolites (Morphine-3-Glucuronide and Morphine-6-Glucuronide). Typically the concentrations of the conjugated metabolites in the blood exceed that of the unconjugated (or free) drug.
8670SP	Opiates - Total (Conjugated/Unconjugated), Serum/Plasma <ul style="list-style-type: none"> • Morphine - Total 	Total Morphine concentrations include unconjugated Morphine plus conjugated metabolites (Morphine-3-Glucuronide and Morphine-6-Glucuronide). Typically the concentrations of the conjugated metabolites in the blood exceed that of the unconjugated (or free) drug.
2302U	Organic Acids Panel, Urine <ul style="list-style-type: none"> • Hippuric Acid (Creatinine corrected) • Mandelic Acid (Creatinine corrected) • Phenylglyoxylic Acid (Creatinine corrected) 	<p>Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 1.6 g Hippuric Acid/g Creatinine measured in an end of shift specimen.</p> <p>Biological Exposure Index (ACGIH) for monitoring exposure to Ethylbenzene: 1.5 g Mandelic Acid/g Creatinine measured in an end of shift at end of workweek specimen. For monitoring exposure to Styrene: Mandelic Acid plus Phenylglyoxylic Acid: 0.4 g/g Creatinine measured in an end of shift specimen.</p> <p>Biological Exposure Index (ACGIH) for monitoring exposure to Styrene: Mandelic Acid plus Phenylglyoxylic Acid: 0.4 g/g Creatinine measured in an end of shift specimen.</p>
3250SP	Oxalate, Serum/Plasma <ul style="list-style-type: none"> • Oxalate 	Reference range: Normally up to 27 umol/L.

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
3270B	Oxycodone, Blood <ul style="list-style-type: none">• Oxycodone	<p>Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL.</p> <p>Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL.</p> <p>Mean peak plasma concentrations following a single dose of a 40 to 80 mg controlled-release Oxycodone preparation: 39 - 100 ng/mL.</p> <p>Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.</p>
3270SP	Oxycodone, Serum/Plasma <ul style="list-style-type: none">• Oxycodone	<p>Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL.</p> <p>Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL.</p> <p>Mean peak plasma concentrations following a single dose of a 40 to 80 mg controlled-release Oxycodone preparation: 39 - 100 ng/mL.</p> <p>Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
8667B	Oxycodone and Metabolite, Blood <ul style="list-style-type: none">Oxycodone	<p>Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL.</p> <p>Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL.</p> <p>Mean peak plasma concentrations following a single dose of a 40 to 80 mg controlled-release Oxycodone preparation: 39 - 100 ng/mL.</p> <p>Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.</p>
8667SP	Oxycodone and Metabolite, Serum/Plasma <ul style="list-style-type: none">Oxycodone	<p>Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL.</p> <p>Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL.</p> <p>Mean peak plasma concentrations following a single dose of a 40 to 80 mg controlled-release Oxycodone preparation: 39 - 100 ng/mL.</p> <p>Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
5557B	Oxycodone Confirmation, Blood <ul style="list-style-type: none"> Oxycodone 	<p>Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL.</p> <p>Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL.</p> <p>Mean peak plasma concentrations following a single dose of a 40 to 80 mg controlled-release Oxycodone preparation: 39 - 100 ng/mL.</p> <p>Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.</p>
5557SP	Oxycodone Confirmation, Serum/Plasma <ul style="list-style-type: none"> Oxycodone 	<p>Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL.</p> <p>Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL.</p> <p>Mean peak plasma concentrations following a single dose of a 40 to 80 mg controlled-release Oxycodone preparation: 39 - 100 ng/mL.</p> <p>Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.</p>
3292B	Palladium, Blood <ul style="list-style-type: none"> Palladium 	<p>Blood concentrations in non-occupationally exposed individuals: Less than 0.1 mcg/L.</p>
3292R	Palladium, RBCs <ul style="list-style-type: none"> Palladium 	<p>Blood concentrations in non-occupationally exposed individuals: Less than 0.1 mcg/L.</p>
3292SP	Palladium, Serum/Plasma <ul style="list-style-type: none"> Palladium 	<p>Blood concentrations in non-occupationally exposed individuals: Less than 0.1 mcg/L.</p>
3292U	Palladium, Urine <ul style="list-style-type: none"> Palladium 	<p>Urine concentrations in non-occupationally exposed individuals: Up to 0.3 mcg/L.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
3430B	Perchloroethylene, Blood <ul style="list-style-type: none"> Perchloroethylene 	Biological Exposure Index (ACGIH): 0.5 mcg/mL in blood specimen collected prior to last shift of workweek.
3430SP	Perchloroethylene, Serum/Plasma <ul style="list-style-type: none"> Perchloroethylene 	Biological Exposure Index (ACGIH): 0.5 mcg/mL in blood specimen collected prior to last shift of workweek.
3435B	Percocet, Blood <ul style="list-style-type: none"> Oxycodone 	Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL. Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL. Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.
3435SP	Percocet, Serum/Plasma <ul style="list-style-type: none"> Oxycodone 	Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL. Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL. Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.
3436B	Percodan, Blood <ul style="list-style-type: none"> Oxycodone 	Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL. Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL. Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
3436SP	Percodan, Serum/Plasma <ul style="list-style-type: none"> Oxycodone 	<p>Peak plasma concentrations 1 hour after a single immediate-release tablet preparation containing 5 mg of Oxycodone: 9 - 38 ng/mL.</p> <p>Peak plasma concentrations within 2.5 hours after 10 mg of an immediate-release preparation of Oxycodone: 13 - 46 ng/mL.</p> <p>Toxicity may be significant at greater than 200 ng/mL. However, concentrations associated with toxicity are variable and depend on an individual's tolerance to the drug.</p>
3580B	Phenobarbital, Blood <ul style="list-style-type: none"> Phenobarbital 	<p>Anticonvulsant range (serum/plasma): 10 - 30 mcg/mL. Blood to plasma ratio: 0.81.</p>
3580SP	Phenobarbital, Serum/Plasma <ul style="list-style-type: none"> Phenobarbital 	<p>Anticonvulsant range: 10 - 30 mcg/mL.</p>
3584SP	Phenobarbital, Serum/Plasma <ul style="list-style-type: none"> Phenobarbital 	<p>Anticonvulsant range: 10 - 30 mcg/mL.</p>
8633B	Phenobarbital, Blood <ul style="list-style-type: none"> Phenobarbital 	<p>Anticonvulsant range (serum/plasma): 10 - 30 mcg/mL. Blood to plasma ratio: 0.81.</p>
8633SP	Phenobarbital, Serum/Plasma <ul style="list-style-type: none"> Phenobarbital 	<p>Anticonvulsant range: 10 - 30 mcg/mL.</p>
5544B	Phenobarbital Confirmation, Blood <ul style="list-style-type: none"> Phenobarbital 	<p>Anticonvulsant range (serum/plasma): 10 - 30 mcg/mL. Blood to plasma ratio: 0.81.</p>
5544SP	Phenobarbital Confirmation, Serum/Plasma <ul style="list-style-type: none"> Phenobarbital 	<p>Anticonvulsant range: 10 - 30 mcg/mL.</p>
9416B	Phenobarbital Screen, Blood <ul style="list-style-type: none"> Phenobarbital 	<p>Anticonvulsant range (serum/plasma): 10 - 30 mcg/mL. Blood to plasma ratio: 0.81.</p>
9416SP	Phenobarbital Screen, Serum/Plasma <ul style="list-style-type: none"> Phenobarbital 	<p>Anticonvulsant range: 10 - 30 mcg/mL.</p>
3621U	Phenol Exposure, Urine <ul style="list-style-type: none"> Phenol (Creatinine corrected) 	<p>Biological Exposure Index (ACGIH): 250 mg Phenol/g Creatinine measured in an end of shift urine.</p>

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
5545SP	Phenothiazines Confirmation, Serum/Plasma <ul style="list-style-type: none"> Thioridazine 	Steady-state serum concentration during chronic oral administration of 400 mg daily: 140 - 2600 ng/mL. Therapeutic steady-state concentrations may overlap levels associated with toxicity.
8680B	Phenothiazines Panel, Blood <ul style="list-style-type: none"> Thioridazine 	Steady-state serum concentration during chronic oral administration of 400 mg daily: 140 - 2600 ng/mL. Therapeutic steady-state concentrations may overlap levels associated with toxicity.
8680SP	Phenothiazines Panel, Serum/Plasma <ul style="list-style-type: none"> Thioridazine 	Steady-state serum concentration during chronic oral administration of 400 mg daily: 140 - 2600 ng/mL. Therapeutic steady-state concentrations may overlap levels associated with toxicity.
9420SP	Phenothiazines Screen, Serum/Plasma <ul style="list-style-type: none"> Thioridazine 	Steady-state serum concentration during chronic oral administration of 400 mg daily: 140 - 2600 ng/mL. Therapeutic steady-state concentrations may overlap levels associated with toxicity.
3900B	Primidone, Phenobarbital and PEMA, Blood <ul style="list-style-type: none"> Phenobarbital 	Anticonvulsant range (serum/plasma): 10 - 30 mcg/mL. Blood to plasma ratio: 0.81.
3900SP	Primidone, Phenobarbital and PEMA, Serum/Plasma <ul style="list-style-type: none"> Phenobarbital 	Anticonvulsant range: 10 - 30 mcg/mL.
4070SP	Quinidine, Serum/Plasma <ul style="list-style-type: none"> Quinidine 	Usual therapeutic range: 2 - 6 mcg/mL. Toxicity generally seen at concentrations greater than 8 mcg/mL. Quinine and Quinidine are stereoisomers and are not differentiated in this analysis. Quinine and Quinidine can be differentiated analytically by a separate analysis. If further delineation is necessary, please contact the laboratory.
4071SP	Quinidine, Serum/Plasma <ul style="list-style-type: none"> Quinidine 	Usual therapeutic range: 2 - 6 mcg/mL. Toxicity generally seen at concentrations greater than 8 mcg/mL.
4072SP	Quinidine, Serum/Plasma <ul style="list-style-type: none"> Quinidine 	Usual therapeutic range: 2 - 6 mcg/mL. Toxicity generally seen at concentrations greater than 8 mcg/mL.

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
4075SP	Quinine/Quinidine Differentiation, Serum/Plasma <ul style="list-style-type: none"> Quinidine 	Usual therapeutic range: 2 - 6 mcg/mL. Toxicity generally seen at concentrations greater than 8 mcg/mL.
5434SP	Quinine/Quinidine Confirmation, Serum/Plasma <ul style="list-style-type: none"> Quinidine 	Usual therapeutic range: 2 - 6 mcg/mL. Toxicity generally seen at concentrations greater than 8 mcg/mL.
5435SP	Quinine/Quinidine Confirmation, Serum/Plasma (Forensic) <ul style="list-style-type: none"> Quinidine 	Usual therapeutic range: 2 - 6 mcg/mL. Toxicity generally seen at concentrations greater than 8 mcg/mL.
4124SP	Rubidium, Serum/Plasma <ul style="list-style-type: none"> Rubidium 	Usually 8 - 56 mcg/dL.
6317U	Semi-Conductor Panel, Urine <ul style="list-style-type: none"> Tellurium 	Less than 1 mcg/L in non-occupationally exposed individuals.
4200R	Silver, RBCs <ul style="list-style-type: none"> Silver 	Reference range: Less than 6 mcg/L blood.
0871B	Solvent Exposure Profile, Blood <ul style="list-style-type: none"> Perchloroethylene Toluene 	Biological Exposure Index (ACGIH): 0.5 mcg/mL in blood specimen collected prior to last shift of workweek. Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
0872U	Solvent Profile, Urine <ul style="list-style-type: none"> • o-Cresol • Hippuric Acid (Creatinine corrected) • Mandelic Acid (Creatinine corrected) • Phenylglyoxylic Acid (Creatinine corrected) • Phenol (Creatinine corrected) • S-Phenylmercapturic Acid (Creatinine corrected) • t,t-Muconic Acid (Creatinine corrected) 	<p>Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 0.5 mg o-Cresol/L urine measured in an end of shift specimen.</p> <p>Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 1.6 g Hippuric Acid/g Creatinine measured in an end of shift specimen.</p> <p>Biological Exposure Index (ACGIH) for monitoring exposure to Ethylbenzene: 1.5 g Mandelic Acid/g Creatinine measured in an end of shift at end of workweek specimen. For monitoring exposure to Styrene: Mandelic Acid plus Phenylglyoxylic Acid: 0.4 g/g Creatinine measured in an end of shift specimen.</p> <p>Biological Exposure Index (ACGIH) for monitoring exposure to Styrene: Mandelic Acid plus Phenylglyoxylic Acid: 0.4 g/g Creatinine measured in an end of shift specimen.</p> <p>Biological Exposure Index (ACGIH): 250 mg Phenol/g Creatinine measured in an end of shift urine.</p> <p>Biological Exposure Index (ACGIH) for monitoring exposure to Benzene: 25 mcg S-Phenylmercapturic Acid/g Creatinine measured in an end of shift specimen.</p> <p>Biological Exposure Index (ACGIH) for monitoring exposure to Benzene: 500 mcg t,t-Muconic Acid/g Creatinine measured in an end of shift specimen.</p>
4232B	Styrene, Blood <ul style="list-style-type: none"> • Styrene 	<p>Biological Exposure Index (ACGIH): 0.2 mcg/mL in blood specimen collected in an end of shift specimen.</p>
4232SP	Styrene, Serum/Plasma <ul style="list-style-type: none"> • Styrene 	<p>Biological Exposure Index (ACGIH): 0.2 mcg/mL in blood specimen collected in an end of shift specimen. Note: Blood is the appropriate specimen for this test.</p>

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
4213U	Styrene Exposure Profile, Urine <ul style="list-style-type: none"> Mandelic Acid (Creatinine corrected) Phenylglyoxylic Acid (Creatinine corrected) 	[Reference comment was removed.] Biological Exposure Index (ACGIH): Mandelic Acid plus Phenylglyoxylic Acid: 0.4 g/g Creatinine measured in an end of shift specimen.
4230U	Styrene Exposure Survey, Urine <ul style="list-style-type: none"> Mandelic Acid (Creatinine corrected) Phenylglyoxylic Acid (Creatinine corrected) 	[Reference comment was removed.] Biological Exposure Index (ACGIH): Mandelic Acid plus Phenylglyoxylic Acid: 0.4 g/g Creatinine measured in an end of shift specimen.
4320U	Tellurium, Urine <ul style="list-style-type: none"> Tellurium 	Less than 1 mcg/L urine in non-occupationally exposed individuals.
4450B	Thiopental and Metabolite, Blood <ul style="list-style-type: none"> Pentobarbital 	Therapeutic (sedation) range: 1 - 5 mcg/mL Toxic: Greater than 10 mcg/mL.
4450SP	Thiopental and Metabolite, Serum/Plasma <ul style="list-style-type: none"> Pentobarbital 	Therapeutic (sedation) range: 1 - 5 mcg/mL Toxic: Greater than 10 mcg/mL.
4461B	Thioridazine and Metabolite, Blood <ul style="list-style-type: none"> Thioridazine 	Steady-state serum concentration during chronic oral administration of 400 mg daily: 140 - 2600 ng/mL. Therapeutic steady-state concentrations may overlap levels associated with toxicity.
4461SP	Thioridazine and Metabolite, Serum/Plasma <ul style="list-style-type: none"> Thioridazine 	Steady-state serum concentration during chronic oral administration of 400 mg daily: 140 - 2600 ng/mL. Therapeutic steady-state concentrations may overlap levels associated with toxicity.
8689B	Thioridazine and Metabolite, Blood <ul style="list-style-type: none"> Thioridazine 	Steady-state serum concentration during chronic oral administration of 400 mg daily: 140 - 2600 ng/mL. Therapeutic steady-state concentrations may overlap levels associated with toxicity.
8689SP	Thioridazine and Metabolite, Serum/Plasma <ul style="list-style-type: none"> Thioridazine 	Steady-state serum concentration during chronic oral administration of 400 mg daily: 140 - 2600 ng/mL. Therapeutic steady-state concentrations may overlap levels associated with toxicity.
5693B	Thioridazine and Metabolite Confirmation, Blood <ul style="list-style-type: none"> Thioridazine 	Steady-state serum concentration during chronic oral administration of 400 mg daily: 140 - 2600 ng/mL. Therapeutic steady-state concentrations may overlap levels associated with toxicity.

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
5693SP	Thioridazine and Metabolite Confirmation, Serum/Plasma <ul style="list-style-type: none"> Thioridazine 	Steady-state serum concentration during chronic oral administration of 400 mg daily: 140 - 2600 ng/mL. Therapeutic steady-state concentrations may overlap levels associated with toxicity.
9427B	Thioridazine and Metabolite Screen, Blood <ul style="list-style-type: none"> Thioridazine 	Steady-state serum concentration during chronic oral administration of 400 mg daily: 140 - 2600 ng/mL. Therapeutic steady-state concentrations may overlap levels associated with toxicity.
9427SP	Thioridazine and Metabolite Screen, Serum/Plasma <ul style="list-style-type: none"> Thioridazine 	Steady-state serum concentration during chronic oral administration of 400 mg daily: 140 - 2600 ng/mL. Therapeutic steady-state concentrations may overlap levels associated with toxicity.
4510B	Toluene, Blood <ul style="list-style-type: none"> Toluene 	Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.
4510SP	Toluene, Serum/Plasma <ul style="list-style-type: none"> Toluene 	Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.
4511B	Toluene Biouptake Survey, Blood <ul style="list-style-type: none"> Toluene 	Biological Exposure Index (ACGIH): 0.05 mcg Toluene/mL blood measured in a prior to last shift of workweek specimen.
4511U	Toluene Biouptake Survey, Urine <ul style="list-style-type: none"> o-Cresol Hippuric Acid (Creatinine corrected) 	Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 0.5 mg o-Cresol/L urine measured in an end of shift specimen. Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 1.6 g Hippuric Acid/g Creatinine measured in an end of shift specimen.
4512U	Toluene Exposure Panel, Urine <ul style="list-style-type: none"> Hippuric Acid (Creatinine corrected) 	Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 1.6 g Hippuric Acid/g Creatinine measured in an end of shift specimen.

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
4513U	Toluene Exposure Panel, Urine <ul style="list-style-type: none"> o-Cresol 	Biological Exposure Index (ACGIH) for monitoring exposure to Toluene: 0.5 mg o-Cresol/L urine measured in an end of shift specimen.
4531B	Tramadol and Metabolite, Blood <ul style="list-style-type: none"> O-Desmethyltramadol 	Peak plasma concentration following a single 100 mg oral dose: 35 - 75 ng O-Desmethyltramadol/mL. Steady-state plasma concentration following a 100 mg 4 times daily regimen: 80 - 140 ng O-Desmethyltramadol/mL.
4531SP	Tramadol and Metabolite, Serum/Plasma <ul style="list-style-type: none"> O-Desmethyltramadol 	Peak plasma concentration following a single 100 mg oral dose: 35 - 75 ng O-Desmethyltramadol/mL. Steady-state plasma concentration following a 100 mg 4 times daily regimen: 80 - 140 ng O-Desmethyltramadol/mL.
5626B	Tramadol and Metabolite Confirmation, Blood <ul style="list-style-type: none"> O-Desmethyltramadol 	Peak plasma concentration following a single 100 mg oral dose: 35 - 75 ng O-Desmethyltramadol/mL. Steady-state plasma concentration following a 100 mg 4 times daily regimen: 80 - 140 ng O-Desmethyltramadol/mL.
5626SP	Tramadol and Metabolite Confirmation, Serum/Plasma <ul style="list-style-type: none"> O-Desmethyltramadol 	Peak plasma concentration following a single 100 mg oral dose: 35 - 75 ng O-Desmethyltramadol/mL. Steady-state plasma concentration following a 100 mg 4 times daily regimen: 80 - 140 ng O-Desmethyltramadol/mL.
9288B	Tramadol and Metabolite Screen, Blood <ul style="list-style-type: none"> O-Desmethyltramadol 	Peak plasma concentration following a single 100 mg oral dose: 35 - 75 ng O-Desmethyltramadol/mL. Steady-state plasma concentration following a 100 mg 4 times daily regimen: 80 - 140 ng O-Desmethyltramadol/mL.
9288SP	Tramadol and Metabolite Screen, Serum/Plasma <ul style="list-style-type: none"> O-Desmethyltramadol 	Peak plasma concentration following a single 100 mg oral dose: 35 - 75 ng O-Desmethyltramadol/mL. Steady-state plasma concentration following a 100 mg 4 times daily regimen: 80 - 140 ng O-Desmethyltramadol/mL.
4772B	Vicodin, Blood <ul style="list-style-type: none"> Hydrocodone 	Following a single 10 mg oral hydrocodone bitartrate dose: Up to 32 ng/mL at 1.5 hours post-dose.

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
4772SP	Vicodin, Serum/Plasma • Hydrocodone	Following a single 10 mg oral hydrocodone bitartrate dose: Up to 32 ng/mL at 1.5 hours post-dose.
4870B	Zirconium, Blood • Zirconium	Reference range: Normally 1.0 - 2.0 mcg/dL.
4870R	Zirconium, RBCs • Zirconium	Reference range: Approximately 620 mcg/dL.
4870SP	Zirconium, Serum/Plasma • Zirconium	Reference range: Normally 10 - 70 mcg/dL.
2483B	Zolpidem, Blood • Zolpidem	<p>Peak plasma concentrations following single oral 5 and 10 mg doses: 29 - 113 ng/mL (mean = 59 ng/mL) and 58 - 272 ng/mL (mean = 121 ng/mL), respectively, occurring at a mean time of 1.6 hours.</p> <p>Clozapine and haloperidol interfere with Zolpidem in this analysis. The presence of clozapine or haloperidol will adversely affect the quantitation of Zolpidem. If clozapine or haloperidol are potential interferents in this case, call the laboratory for alternate quantitative procedures.</p>
2483SP	Zolpidem, Serum/Plasma • Zolpidem	<p>Peak plasma concentrations following single oral 5 and 10 mg doses: 29 - 113 ng/mL (mean = 59 ng/mL) and 58 - 272 ng/mL (mean = 121 ng/mL), respectively, occurring at a mean time of 1.6 hours.</p> <p>Clozapine and haloperidol interfere with Zolpidem in this analysis. The presence of clozapine or haloperidol will adversely affect the quantitation of Zolpidem. If clozapine or haloperidol are potential interferents in this case, call the laboratory for alternate quantitative procedures.</p>
5796U	Zolpidem Confirmation, Urine • Zolpidem	<p>Less than 1% of a given dose of Zolpidem is excreted unchanged in urine over a 24 hour period. Therefore, the analysis of urine for parent Zolpidem is not recommended for therapeutic drug monitoring, compliance or other related purposes.</p> <p>Clozapine and haloperidol interfere with Zolpidem in this analysis. The presence of clozapine or haloperidol will adversely affect the quantitation of Zolpidem. If clozapine or haloperidol are potential interferents in this case, call the laboratory for alternate quantitative procedures.</p>

Changes effective:
August 1, 2005

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
9498U	Zolpidem Screen, Urine <ul style="list-style-type: none">• Zolpidem	<p>Less than 1% of a given dose of Zolpidem is excreted unchanged in urine over a 24 hour period. Therefore, the analysis of urine for parent Zolpidem is not recommended for therapeutic drug monitoring, compliance or other related purposes.</p> <p>Clozapine and haloperidol interfere with Zolpidem in this analysis. The presence of clozapine or haloperidol will adversely affect the quantitation of Zolpidem. If clozapine or haloperidol are potential interferents in this case, call the laboratory for alternate quantitative procedures.</p>